Major advance for neoadjuvant treatment of melanoma
The PBAC recommends expanding current PBS listing for pembrolizumab immunotherapy to allow neoadjuvant (before surgery) treatment of resected stage IIIB-D melanoma.
Prof Richard Scolyer gains strength from widespread support
Family, friends, colleagues and MIA provide support and strength to Prof Richard Scolyer as he undergoes treatment for a glioblastoma (brain cancer).
MIA researchers share learnings on global stage at ASCO23
Read more about how the MIA team continues to play a leading role in pushing melanoma research boundaries at ASCO23, the world's leading clinical oncology conference.
Prof Richard Scolyer awarded IAP ‘Distinguished Pathologist’ Medal
Read more about why Prof Richard Scolyer AO received the IAP Distinguished Pathologist Medal and watch his inspiring acceptance speech.
Prof Richard Scolyer AO honoured with ASDP Founders’ Award
This is the highest award from the American Society of Dermatopathology, and recognises Prof Scolyer's significant contribution to the field of #dermatopathology.
Expanded PBS access to immunotherapy treatment
Combined immunotherapy ipilimumab and nivolumab is now available on the PBS for all advanced melanoma patients.
Fabulous Fundraisers!
Read more about our amazing MIA fundraisers, including some big adventures planned!
Parliamentary Friends launch
An inspiring day at Parliament House in Canberra for the launch of ‘Parliamentary Friends of Melanoma and Skin Cancer Awareness’.
Stop glamourising tanning
Read how you can help us STOP THE GLAMOURISATION OF TANNING.
Thank you, Community Fundraisers!
A shout out to all our wonderful community fundraisers, who have supported MIA in the last two months.